An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 16 Jul 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease; Psoriasis; Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms VITALITY
- Sponsors AbbVie
- 06 Jul 2017 Planned End Date changed from 6 Dec 2017 to 30 Dec 2017.
- 06 Jul 2017 Planned primary completion date changed from 6 Sep 2017 to 30 Dec 2017.
- 06 Jul 2017 Status changed from recruiting to active, no longer recruiting.